BPG is committed to discovery and dissemination of knowledge
Articles in Press
6/25/2026 7:08:11 AM | Browse: 3 | Download: 4
| Category |
Oncology |
| Manuscript Type |
Basic Study |
| Article Title |
EIF5B/mitogen-activated protein kinase 1 axis drives tumor progression and confers dual resistance to chemotherapy and immunotherapy in colonic adenocarcinoma
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Wen-Xu Li, Qi-Zhong Shi, Yong-Hui Mu, Cheng-Lei Li, Suliman Khan, Wen-Chao Zhao and Na Han |
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Henan Provincial Natural Science Foundation |
No. 252300421368 |
| Top Talents Funding of the Second Affiliated Hospital of Zhengzhou University |
No. 2020BJRCB04 |
| Beijing Science and Technology Innovation Medical Development Foundation |
No. KC2023-JX-0186-FM054 |
|
| Corresponding Author |
Na Han, Chief Physician, MD, PhD, Professor, Department of Oncology, The Second Affiliated Hospital of Zhengzhou University, No. 2 Jingba Road, Jinshui District, Zhengzhou 450014, Henan Province, China. hannahappy@zzu.edu.cn |
| Key Words |
Colonic adenocarcinoma; EIF5B; Mitogen-activated protein kinase 1; Proliferation; Immune infiltration; Drug sensitivity |
| Core Tip |
This study identifies EIF5B as a novel oncogenic driver in colonic adenocarcinoma. EIF5B was upregulated in tumor tissues and associated with poor prognosis. Functional experiments showed that EIF5B promoted tumor cell proliferation, migration, invasion, and xenograft growth by enhancing mitogen-activated protein kinase 1 phosphorylation. High EIF5B expression was also linked to an immunosuppressive tumor microenvironment, lower predicted responses to programmed cell death protein 1/cytotoxic T lymphocyte-associated antigen-4 blockade, and reduced sensitivity to standard chemotherapeutic agents. These findings suggest that EIF5B may serve as both a prognostic biomarker and a therapeutic target for overcoming chemotherapy and immunotherapy resistance in colonic adenocarcinoma. |
| Citation |
Li WX, Shi QZ, Mu YH, Li CL, Khan S, Zhao WC, Han N. EIF5B/mitogen-activated protein kinase 1 axis drives tumor progression and confers dual resistance to chemotherapy and immunotherapy in colonic adenocarcinoma. World J Gastroenterol 2026; In press
|
| PDF |
121829-in-press.pdf
|
 |
Received |
|
2026-04-07 06:15 |
|
Peer-Review Started |
|
2026-04-07 06:16 |
|
First Decision by Editorial Office Director |
|
2026-04-15 08:45 |
|
Return for Revision |
|
2026-04-15 08:45 |
|
Revised |
|
2026-05-08 12:28 |
|
Publication Fee Transferred |
|
2026-05-11 15:26 |
|
Second Decision by Editor |
|
2026-06-25 02:30 |
 |
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2026-06-25 07:08 |
|
Articles in Press |
|
2026-06-25 07:08 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
|
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc. |
| Copyright |
©Author(s) (or their employer(s)) 2026. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc. |
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
